Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 104. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Health insurance system in Japan faces risk of politicisation889
Navigating the complexity: reflections on the development of perioperative cancer treatments639
Dual therapy in metastatic castration-resistant prostate cancer578
US FDA proposes stronger laboratory test oversight557
Enhancing equity and long-term impact assessments in radiotherapy environmental studies495
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer429
Toxicity assessment bias in the PACE-C trial – Authors' reply419
New national cancer registry for France411
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX405
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus387
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial340
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi340
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial333
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges328
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study327
The future of precise cancer chronotherapeutics316
Palliative radiotherapy for hepatic cancer pain300
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply296
SANO trial: innovations, risks, and unanswered questions294
US Surgeon General calls for cancer warning labels on alcohol292
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas283
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia266
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study250
Correction to Lancet Oncol 2021; 22: 1081–92245
Antibody–drug conjugates in acute myeloid leukaemia: more research needed235
Olanzapine for chemotherapy-induced nausea and vomiting control234
Study bolsters concerns about US FDA accelerated drug approvals233
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial232
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis231
Survivorship after neoadjuvant chemotherapy225
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply216
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy216
SABR for operable stage I non-small-cell lung cancer: comparison to surgery213
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer211
Correction to Lancet Oncol 2022; 23: 1124–26207
Combination immunotherapy in chemotherapy in gastric cancer207
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC205
Use of artificial intelligence to enhance detection of nodal metastases202
The silent malignant mesothelioma epidemic: a call to action202
Patients with cancer in Louisiana denied fertility preservation cover201
A new generation of comprehensive precision oncology trials201
The GLOW trial in chronic lymphocytic leukaemia199
Medical treatment for active breast cancer brain metastases193
Precision medicine for children with cancer193
Determining the optimal use of approved drugs in oncology191
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 191
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies183
Concern for cancer drugs in USA–EU tariff war182
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries180
IVLBCL mimicking VEXAS syndrome179
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation179
Italy to pass law on the right to be forgotten for cancer survivors173
Innovation in gynaecological cancer: highlighting global disparities170
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o170
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t169
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult167
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply167
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial164
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 161
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 160
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm159
Focus where it matters: turning insights into advocacy158
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer155
Syrian cancer patients regain treatment access in Türkiye155
A growing vulvar mass in a post-menopausal woman153
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus152
Cancer on the agenda during IAEA Director General's visit to Chile149
Lung cancer rates highest among British Bangladeshi men148
Balancing clinical benefit and social value: challenges in HTA assessments147
Radiotherapy with genomic-adjusted radiation dose145
Mantle cell lymphoma: is it time for risk-adapted treatment?144
Radiotherapy with genomic-adjusted radiation dose143
Correction to Lancet Oncol 2023; 24: e242141
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire140
Clearing the radiotherapy backlog: innovation to pave the way140
2022 ASTRO annual meeting136
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer136
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra135
A biobank perspective on use of tissue samples donated by trial participants134
Common Sense Oncology: including everyone134
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply133
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer133
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?128
Decentralised, point-of-care CAR-T for multiple myeloma128
Correction to Lancet Oncol 2020; 21: 699–709127
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer126
ESMO Congress 2025124
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study124
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA121
Importance of clinical research for the UK's 10-year cancer plan120
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup119
Essential anticancer medicines for children: defining what matters most for Europe118
Oral contraceptives and risk of liver cancer117
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK117
Radiotherapy and conflict: from disruption to expansion and hope117
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group114
Antimicrobial resistance in patients with haematological malignancies: a scoping review113
Daratumumab maintenance in patients with myeloma111
Challenges and prospects for cancer treatment in prison settings109
WHO reports health service disruptions due to suspensions of aid109
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer106
Systemic therapy for brain metastases: a changing landscape106
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations105
India rolls out HPV vaccination104
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study104
0.33273196220398